COPD and microalbuminuria: A 12-year follow-up study

European Respiratory Journal

Volumn 43, Issue 4, 2014, Pages 1042-1050

  Romundstad, Solfrid ^a,b,c   Naustdal, Thor ^a,b   Romundstad, Pål Richard ^c   Sorger, Hanne ^a   Langhammer, Arnulf ^b  

^a Levanger Hospital   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; ALBUMINOID; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ADULT; AGED; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MORTALITY; NORWAY; PRIORITY JOURNAL; PROGNOSIS; SPIROMETRY; TREND STUDY; URINALYSIS; ALBUMINURIA; BODY MASS; COMPLICATION; INFLAMMATION; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINE;

ADULT; AGED; ALBUMINS; ALBUMINURIA; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 84897427592     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00160213     Document Type: Conference Paper

References (36)

1. Mannino D, Buist AS Global burden of COPD: risk factors, prevalence and future trends. Lancet 2009; 370: 765-773.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. www.goldcopd.org/ guidelines-global-strategy-for-diagnosis-management.html Date last accessed: November 2013. Date last updated: February 2013.
3. Johannessen A, Omenaas ER, Bakke P.S., et al Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005; 60: 842-847.
4. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
5. Barnes PJ, Celli BR Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
6. Søyseth V, Brekke P.H., Smith P., et al Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
7. Marin L, Colombo P, Bebawy M., et al Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv 2011; 8: 1205-1220.
8. Mancini GB, Etminan M, Zhang B., et al Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
9. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
10. Gerstein HC, Mann JF, Yi Q, et al Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
11. Jensen JS, Feldt-Rasmussen B, Strandgaard S., et al Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
12. Romundstad S, Holmen J, Hallan H., et al Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway. Circulation 2003; 108: 2783-2789.
13. Pedrinelli R, Dell'Omo G, Penno G, et al. Non-diabetic, microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 2001; 6: 257-264.
14. Diercks GF, van Boven AJ, Hillege JL, et al The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 2002; 18: 525-535.
15. Hallan H, Romundstad S, Kvenild K., et al Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol 2003; 37: 151-158.
16. Krokstad S, Langhammer A, Hveem K., et al Cohort profile: the HUNT Study, Norway. Int J Epidemiol 2013; 42: 968-977.
17. Langhammer A, Johnsen R, Holmen J., et al Cigarette smoking gives more respiratory symptoms among women than among men. The Nord-Trøndelag Health Study (HUNT). J Epidemiol Community Health 2000; 54: 917-922.
18. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
19. Langhammer A, Johnsen R, Gulsvik A., et al Forced spirometry reference values for Norwegian adults: the bronchial obstruction in Nord-Trøndelag Study. Eur Respir J 2001; 18: 770-779.
20. Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003; 13: 19-32.
21. Statistics Norway. Central Bureau of Statistics Kongsvinger, Oslo. www.ssb.no Date last accessed: November 2013.
22. Nitsch D, Grams M, Sang Y., et al Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analyses. BMJ 2013; 346: f324.
23. Faulx MD, Storfer-Isser A, Kirchner H.L., et al Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep 2007; 30: 923-929.
24. Jacobs DR J.r., Murtaugh MA, Steffens M, et al Gender- and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 2002; 155: 1114-1119.
25. Casanova C, de Torres JP, Navarro J, et al Microalbuminuria and hypoxia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1004-1010.
26. Kleinbaum DG. Survival Analysis: A Self Learning Approach. New York, Springer-Verlag, 1996.
27. Bulcun E, Ekici M, Ekici A., et al Microalbuminuria in chronic obstructive pulmonary disease. COPD 2013; 10: 186-192.
28. Kömürcüoǧlu A, Kalenci S, Kalenci D, et al. Microalbuminuria in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 2003; 59: 269-272.
29. Polatli M, Cakir A, Cildag O., et al Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008; 26: 97-102.
30. Cogo A, Ciaccia A, Legorini C., et al Proteinuria in COPD patients with and without respiratory failure. Chest 2003; 123: 652-653.
31. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313.
32. Jensen JS, Clausen P, Borch-Johnsen K, et al Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997; 12: Suppl. 2, 6-9.
33. Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag 2007; 3: 783-795.
34. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2012. Diabetes Care 2012; 35: Suppl. 1, S4-S10.
35. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008; 62: 97-108.
36. Brouwers FP, Asselbergs FW, Hillege H.L., et al Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011; 161: 1171-1178.